Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : OSI Pharmaceuticals (OSIP) - formerly Oncogene -- Ignore unavailable to you. Want to Upgrade?

To: IRWIN JAMES FRANKEL who wrote (237)	1/27/2005 5:03:42 PM
From: IRWIN JAMES FRANKEL	Read Replies (1) \| Respond to of 447

ZURICH (Dow Jones)--Roche Holding AG (RHHBY) said Thursday that data from a study indicates that its Tarceva treatment improves survival in patients with pancreatic cancer in an advanced stage, or when it has spread to other parts of the body. The data was presented at the American Society of Clinical Oncology, or ASCO's, Gastrointestinal Cancers Symposium in Floria. There was a statistically significant increase of 23.5% in overall survival in patients with locally advanced or metastatic pancreatic cancer who received Tarceva plus gemcitabine, compared to patients receiving gemcitabine alone. A higher percentage of patients were alive at 12 months in the group treated with Tarceva plus gemcitabine, compared to those treated with chemotherapy alone. Progression-free survival was also significantly improved for patients treated with Tarceva. Pancreatic cancer is the fourth leading cause of all cancer deaths; in Europe each year 60,000 people are diagnosed with pancreatic cancer and current treatment options are limited. The multi-center, randomized, double-blind, placebo-controlled Phase III international study was conducted by the National Cancer Institute of Canada, Clinical Trials Group at Queens University in collaboration with OSI Pharmaceuticals. The study evaluated Tarceva at 100mg per day or 150mg per day in patients with locally advanced or metastatic pancreatic cancer. Patients received either gemcitabine with Tarceva or gemcitabine plus placebo. A total of 569 patients were randomised into the study, with 521 patients receiving 100mg per day Tarceva or placebo and 48 patients receiving 150mg per day Tarceva or placebo. Tarceva is currently being evaluated in an extensive clinical development programme by a global alliance among OSI Pharmaceuticals Inc (OSIP), Genentech Inc (DNA), and Roche. Chugai Pharmaceutical Co Ltd. (4519.TO) is pursuing its development and regulatory approval for the Japanese market.

To: IRWIN JAMES FRANKEL who wrote (237)	10/17/2005 1:53:57 PM
From: tuck	Respond to of 447

"Current Knowledge and Future Directions of the Selective Epidermal Growth Factor Receptor Inhibitors Erlotinib (Tarceva®) and Gefitinib (Iressa®)" theoncologist.alphamedpress.org Full text freebie. Wonder why the dosing regimen used in combo trials in humans for NSCLC -- which failed -- was so different than that used in peclinical studies -- which looked good? Here's another recent commentary: "The Current Situation: Erlotinib (Tarceva®) and Gefitinib (Iressa®) in Non-Small Cell Lung Cancer" theoncologist.alphamedpress.org Cheers, Tuck